http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107238712-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-324 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2017-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107238712-B |
| titleOfInvention | Application of the blood plasma S100A12 in ST sections of elevation myocardial infarction prognosis |
| abstract | The invention belongs to the application of Medical Biology technical field more particularly to S100A12 albumen in ST sections of elevation myocardial infarction (STEMI) prognosis.The S100A12 albumen can be used as the biomarker of ST sections of elevation myocardial infarction prognosis；Specifically, the S100A12 albumen can be used for preparing the kit of ST sections of elevation myocardial infarction prognosis.The follow-up that the present invention has carried out MACCE event in morbidity 1 year to STEMI patient is tested, and the correlation of S100A12 level and STEMI patient's prognosis in blood plasma is inquired into, and provides a good prediction index for assessment STEMI patient's prognosis. |
| priorityDate | 2017-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 151.